Q-omics provides the consensus-scored TNFRSF10A profile across patient tissues and cancer cell-line models. TNFRSF10A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TNFRSF10A is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, TNFRSF10A RNA expression shows 18,298 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KIRC, and THYM as cancer lineages where TNFRSF10A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNFRSF10A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNFRSF10A survival associations across molecular data types. TNFRSF10A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNFRSF10A RNA expression–survival associations across cancer types. High TNFRSF10A expression shows unfavorable associations in MESO, LGG, PAAD, LUAD and STAD, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for TNFRSF10A RNA expression.
This table summarizes TNFRSF10A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TNFRSF10A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNFRSF10A shows lower tumor expression in KICH and higher tumor expression in KIRC, COAD, THCA, STAD and HNSC. The KIRC box plot shows higher TNFRSF10A RNA expression in tumor versus normal tissue (log2 FC = +0.982, t-test p < 0.001).
This table shows molecular features associated with TNFRSF10A in patient tissues and cancer cell lines. In patient samples, TNFRSF10A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TNFRSF10A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
